Close Menu

Danaher said that it expects its first quarter adjusted EPS to exceed the high end of its previous guidance. During its Q4 2017 and full-year 2017 earnings announcement in January, the company said that adjusted EPS for Q1 2018 was anticipated to be in the range of $.90 to $.93.

Danaher President and CEO Thomas Joyce said this week that the firm has started the year strongly from a core revenue and margin perspective. He noted the Life Sciences and Diagnostics segment, especially Cepheid, as main drivers for the new guidance.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.